World

South Korea to receive new helicopters from the US to counter North Korean submarines

Jan 30, 2025

Seoul [South Korea], January 30: In 2020, South Korean defense officials approved a 960 billion won ($667.6 million) project to purchase 12 MH-60R Seahawk helicopters from US defense giant Lockheed Martin to enhance the navy's anti-submarine warfare capabilities, according to Yonhap News Agency.
Of the 12 MH-60R Seahawk helicopters ordered, the first is expected to arrive in South Korea in February, and the remaining are expected to be delivered in stages, according to an official from South Korea's Defense Acquisition Program Administration (DAPA).
The Seahawk helicopter is expected to enter service next year after undergoing field trials and related procedures.
Equipped with AGM-114 Hellfire missiles, Mark 54 lightweight torpedoes and a sonar system, the MH-60R Seahawk will operate alongside the Navy's P-8A maritime patrol aircraft, enhancing surveillance and defense against "North Korean submarine threats," according to Yonhap.
The MH-60R Seahawk is also expected to enhance the operational capabilities of the Republic of Korea Navy as it has a longer flight time than the Lynx and AW159 Wildcat helicopters currently in service, according to DAPA.
Yonhap quoted South Korean officials as saying that North Korea is operating a fleet of about 70 submarines, many of which are small and old.
Pyongyang has recently focused on improving its submarine capabilities, unveiling what it claims is a tactical nuclear attack submarine by 2023, according to Yonhap.
Source: Thanh Nien Newspaper

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026